UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Current Report
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
|
The (Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On April 14, 2025, Health In Tech, Inc., a Nevada corporation (the “Company”) issued a press release announcing its results of operations for the quarter ended March 31, 2025, attached hereto as Exhibit 99.1.
Item 7.01. Regulation FD Disclosure.
As disclosed in Item 2.02 above, on April 14, 2025, the Company issued a press release announcing its results of operations for the quarter ended March 31, 2025, attached hereto as Exhibit 99.1. The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Forward-Looking Statements
Certain statements in this Current Report on Form 8-K are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause the Company’s actual results to differ materially from those presented in its forward-looking statements are set forth in the “Risk Factors” section in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in the Company’s subsequent reports. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
| Exhibit No. | Description | |
| 99.1 | Press release dated April 14, 2025. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 14, 2025
HEALTH IN TECH, INC.
| By: | /s/ Tim Johnson | |
| Name: | Tim Johnson | |
| Title: | Chief Executive Officer |
2
Exhibit 99.1
Health In Tech Announces First Quarter 2025 Financial Results
| ● | Revenues increased 56% over the first quarter 2024 to $8.0 million, reflecting strong market demand |
| ● | Income before income taxes more than tripled to $0.7 million, up 257% over the first quarter 2024 |
| ● | Cash position remained strong at $7.6 million as of March 31, 2025 |
Stuart, FL., April 14, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced its financial results for the first quarter ended March 31, 2025.
Financial Highlights for the First Quarter of 2025
| ● | The number of enrolled employees (EEs) billed was 24,307, compared to 20,802 in the same period of 2024. |
| ● | Total revenues were $8.0 million, 56% YoY growth. |
| ● | Income before income tax expense was $0.7 million, 8.5% of revenue, compared to $0.2 million, 3.7% of revenue in the same period of 2024 |
| ● | Adjusted EBITDA was $1.2 million, compared to $0.5 million in the same period of 2024 |
| ● | Cash and cash equivalents were $7.6 million as of March 31, 2025, compared to $7.8 million as of December 31,2024. |
| ● | Accounts receivable was $2.1 million as of March 31, 2025, with 28 days of AR days, compared to $1.6 million, 29 days of AR days as of December 31, 2024. |
“We’re off to a strong start in 2025,” said Tim Johnson, CEO of Health In Tech. “First-quarter revenue grew 56% over the first quarter 2024, and income before income tax reached $0.7 million—8.5% of revenue—marking a 257% increase from the same period last year.”
“Our momentum continues to build post-IPO, validating the strategic initiatives we’ve executed. Innovations in our platform, product development, and market expansion are driving meaningful results and laying the groundwork for long-term growth. These gains reflect the strategic investments we made in 2024, particularly in product and service innovation, IT enhancements, infrastructure, cybersecurity, and internal controls. With these foundations in place, we’re now scaling efficiently and reaching a wider market.”
Tim continued: “Since beginning beta development of our large-group third-party AI-powered underwriting platform in November 2024, we’ve seen strong interest from the market. Even in its early stages, we successfully delivered solutions in Q1 to large employers, including one with over 1,000 employees. We’re on track for a full rollout in Q3, marking a major milestone as we broaden our total addressable market and provide smarter, faster quoting for mid-sized and large employers.”
“As we move forward, we’re accelerating new program development and expanding our broker and TPA network to grow our national footprint. With a robust pipeline and sustained momentum, we expect continued strong growth in Q2 2025. We remain dedicated to delivering exceptional value, innovation, and service as we scale.”
Recent Developments and Business Highlights
| ● | Partnerships and Collaborations. On March 25, 2025, the Company announced a strategic collaboration with DialCare, a leading provider of telehealth and virtual care solutions. Through this partnership, DialCare’s virtual primary care, therapy, and psychiatry services will be integrated into Health In Tech’s self-funded health plan offerings. Members across the U.S. will gain on-demand access to licensed physicians, therapists and psychiatric providers via phone or video consultations. This collaboration further enhances the Company’s mission to deliver smarter, more accessible healthcare solutions for diverse populations. |
| ● | Appointment of Sanjay Shrestha to Board of Directors. On April 10, 2025, the Company announced the appointment of Sanjay Shrestha to its Board of Directors. Mr. Shrestha brings extensive leadership experience in scaling platform-based businesses and driving growth across the energy and technology sectors. He currently serves as President of Plug Power, having joined the company in 2019 as Chief Strategy Officer. He has played a pivotal role in driving growth and expanding value for both customers and shareholders. As General Manager, he significantly broadened the company’s product portfolio and built out the Energy business to deliver end-to-end solutions—including electrolyzers, liquefiers, and cryogenic systems—while overseeing the development of Plug’s hydrogen production facilities. In addition to his operational expertise, Mr. Shrestha has a strong capital market background, having served as a top-ranked renewables research analyst at Lazard Capital Markets and First Albany Capital. His appointment adds valuable industry and financial expertise to the Board and further strengthens Health In Tech’s strategic vision for long-term growth and market expansion. |
Conference Call Details
Health In Tech will host a conference call to discuss the financial results for the first quarter of 2025 on April 14, 2025 at 5:00 p.m. (ET). To participate in our live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).
A live audio webcast will be available via the Investor Relations page of Health In Tech’s website at https://healthintech.com/. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
2
Non-GAAP Financial Information
This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.
Use of Forward-Looking Statements
Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.
About Health In Tech
Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.
3
Health In Tech, Inc.
Consolidated Statements of Operations
(Unaudited)
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenues | ||||||||
| Revenues from underwriting modeling (ICE) | $ | 2,351,984 | $ | 1,784,635 | ||||
| Revenues from fees | 5,663,000 | 3,340,296 | ||||||
| SMR | 5,663,000 | 2,532,922 | ||||||
| HI Card | - | 807,374 | ||||||
| Total revenues | 8,014,984 | 5,124,931 | ||||||
| Cost of revenues | 2,659,585 | 989,911 | ||||||
| Gross profit | 5,355,399 | 4,135,020 | ||||||
| Operating expenses | ||||||||
| Sales and marketing expenses | 1,090,255 | 1,043,208 | ||||||
| General and administrative expenses | 3,246,765 | 1,999,194 | ||||||
| Research and development expenses | 537,721 | 760,196 | ||||||
| Total operating expenses | 4,874,741 | 3,802,598 | ||||||
| Other income (expense): | ||||||||
| Interest income | 85,366 | 24,312 | ||||||
| Interest expenses | - | (165,000 | ) | |||||
| Other income | 118,399 | - | ||||||
| Total other income (expense), net | 203,765 | (140,688 | ) | |||||
| Income before income tax expense | $ | 684,423 | $ | 191,734 | ||||
| Provision for income taxes | (185,831 | ) | (91,198 | ) | ||||
| Net income | $ | 498,592 | $ | 100,536 | ||||
| Net income per share | ||||||||
| Basic | $ | 0.01 | - | |||||
| Diluted | $ | 0.01 | - | |||||
| Weighted average common stocks outstanding | ||||||||
| Basic | 54,619,858 | 51,769,358 | ||||||
| Diluted | 56,996,936 | 51,769,358 | ||||||
4
Health In Tech, Inc.
Consolidated Balance Sheets
(Unaudited)
| March 31, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 7,575,037 | $ | 7,849,248 | ||||
| Accounts receivable, net | 2,110,601 | 1,647,103 | ||||||
| Other receivables | 3,989,788 | 500,252 | ||||||
| Deferred offering costs | 91,500 | - | ||||||
| Prepaid expenses and other current assets | 1,804,912 | 787,161 | ||||||
| Total current assets | 15,571,838 | 10,783,764 | ||||||
| Non-current assets | ||||||||
| Software | 4,736,093 | 3,962,461 | ||||||
| Loans receivable, net | 831,994 | 815,995 | ||||||
| Operating lease - right of use assets | 190,275 | 206,269 | ||||||
| Total non-current assets | 5,758,362 | 4,984,725 | ||||||
| Total assets | $ | 21,330,200 | $ | 15,768,489 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 5,478,888 | $ | 1,858,840 | ||||
| Income taxes payable | 425,556 | 205,253 | ||||||
| Operating lease liabilities - current | 69,122 | 66,881 | ||||||
| Other current liabilities | 780,045 | - | ||||||
| Total current liabilities | 6,753,611 | 2,130,974 | ||||||
| Non-current liabilities | ||||||||
| Deferred tax liabilities | 294,203 | 328,676 | ||||||
| Operating lease liabilities - non-current | 121,595 | 139,811 | ||||||
| Total non-current liabilities | 415,798 | 468,487 | ||||||
| Total liabilities | 7,169,409 | 2,599,461 | ||||||
| Stockholders’ equity | ||||||||
| Common stock, $0.001 par value; Class A Common stock 150,000,000 shares authorized, 42,973,204 and 42,914,870 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 42,973 | 42,915 | ||||||
| Common stock, $0.001 par value; Class B Common stock 50,000,000 shares authorized, 11,700,000 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 11,700 | 11,700 | ||||||
| Additional paid-in capital | 9,666,130 | 9,173,017 | ||||||
| Retained earnings | 4,439,988 | 3,941,396 | ||||||
| Total stockholders’ equity | 14,160,791 | 13,169,028 | ||||||
| Total liabilities and stockholders’ equity | $ | 21,330,200 | $ | 15,768,489 | ||||
5
Health In Tech, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income | $ | 498,592 | $ | 100,536 | ||||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||
| Amortization expense | 135,983 | 134,787 | ||||||
| Provision for potential revenue reduction | 780,045 | - | ||||||
| Deferred tax benefits | (34,473 | ) | (60,070 | ) | ||||
| Amortization of debt discount | - | 165,000 | ||||||
| Interest income | (15,999 | ) | (15,999 | ) | ||||
| Stock-based compensation expense | 493,171 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (463,498 | ) | 221,102 | |||||
| Other receivables | (3,489,536 | ) | 237,093 | |||||
| Prepaid expenses and other current assets | (1,017,751 | ) | (89,988 | ) | ||||
| Operating lease right of use assets and liabilities, net | 19 | 624 | ||||||
| Accounts payable and accrued expenses | 3,420,497 | (1,485,329 | ) | |||||
| Income taxes payable | 220,303 | 112,032 | ||||||
| Net cash provided by (used in) operating activities | 527,353 | (680,212 | ) | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Development of software | (703,475 | ) | (133,394 | ) | ||||
| Net cash used in investing activities | (703,475 | ) | (133,394 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Payments of deferred offering costs | (98,089 | ) | (243,210 | ) | ||||
| Net cash used in financing activities | (98,089 | ) | (243,210 | ) | ||||
| Decrease in cash and cash equivalents | (274,211 | ) | (1,056,816 | ) | ||||
| Cash and cash equivalents, beginning of year | 7,849,248 | 2,416,350 | ||||||
| Cash and cash equivalents, end of year | 7,575,037 | 1,359,534 | ||||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | $ | - | $ | - | ||||
| Cash paid for income taxes | $ | - | $ | 39,235 | ||||
| Summary of noncash investing and financing activities: | ||||||||
| Accrued deferred offering costs included in accounts payable and accrued expenses | $ | 33,250 | $ | 110,044 | ||||
| Accrued development of software included in accounts payable and accrued expenses | $ | 256,140 | $ | 9,500 | ||||
6
Components of Operating Results
Revenues
While our revenue this quarter primarily comes from underwriting activities and program fees associated with customized healthcare plans for small businesses, our growth is driven by delivering solutions that streamline sales processes, enhance service delivery, and shorten the sales cycle for TPAs, MGUs, and brokers. We offer our services through our three subsidiaries. Program services provided by SMR and MGU activities provided by ICE (including eDIYBS) are interdependent, as they cannot function effectively without being combined. Services provided by HI Card is an optional add-on to our other services, and it cannot be offered on a standalone basis. Brokers that utilize the program services on behalf of the small employer provided by SMR and MGU activities provided by ICE, are not obligated to utilize our HI Card service. Currently ICE does not offer underwriting services as a standalone service. In the future, we may consider offering it as a standalone service.
Cost of revenues
Cost of revenues primarily consists of infrastructure costs to operate our platform such as hosting fees and fees paid to various third-party partners for access to their technology, services and amortization expenses of our capitalized internal-use software related to our platform. We mainly outsource captive management services and data services from the third-party companies. Our internal proprietary system seeks to consistently improve underwriting and services results through machine learning and data feeds. The captive management activities include introducing new carriers, conducting due diligence on carriers, conducting feasibility studies to determine the viability to be a stop-loss carrier on the platform, negotiating terms and contracts, coordinating audit requests, managing relationship with unrelated carriers and their regulators and auditor firms to ensure that our risk associated with our service offerings is minimized.
Sales and marketing expenses
Sales and marketing expenses primarily consist of personnel-related costs including salaries, benefits and commissions cost for our sales and marketing personnel. Sales and marketing expenses also include the costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party for sales and customer acquisition.
General and administrative expenses
General and administrative expenses primarily consist of personnel-related costs and related expenses for our executives, finance, legal, human resources, technical support, and administrative personnel as well as the costs associated with professional fees for external legal, accounting and other consulting services, insurance premiums.
Research and development expenses
Research and development expenses primarily consist of personnel-related costs, including salaries and benefits for our research and development personnel. Additional expenses include costs related to the software development, quality assurance, and testing of new technology, and enhancement of our existing platform technology.
Adjusted EBITDA
Adjusted EBITDA represents our earnings from continuing operations before net interest expense, taxes, and depreciation and amortization expense, adjusted to eliminate stock-based compensation expense and public company readiness costs not deemed capitalizable. Adjusted EBITDA is not a measure calculated in accordance with United States Generally Accepted Accounting Principles, or GAAP. We exclude certain non-recurring or non-cash items when calculating Adjusted EBITDA, and we believe this approach provides a more meaningful measure by offering a clearer view of our underlying operational performance.
Financial Results Summary
(Unaudited)
($ in millions)
| Three Months Ended March 31, | ||||||||||||
| 2025 | 2024 | % Change | ||||||||||
| Total revenues | $ | 8.0 | $ | 5.1 | 56.4 | % | ||||||
| GAAP gross margin | 66.8 | % | 80.7 | % | -13.9 | % | ||||||
| Income before income tax expense | $ | 0.7 | $ | 0.2 | 257.0 | % | ||||||
| Adjusted EBITDA | $ | 1.2 | $ | 0.5 | 163 | % | ||||||
Investor Contact
Investor Relations:
[email protected]
7